Screening for Leishmania specific antibodies among patients with rheumatic diseases treated with biological therapy.

IF 1.3 Q4 RHEUMATOLOGY
Fruzsina Szabados, Henrik Vedel Nielsen, Kurt Fuursted, Asta Linauskas, Claus Rasmussen, Peter Derek Christian Leutscher
{"title":"Screening for Leishmania specific antibodies among patients with rheumatic diseases treated with biological therapy.","authors":"Fruzsina Szabados, Henrik Vedel Nielsen, Kurt Fuursted, Asta Linauskas, Claus Rasmussen, Peter Derek Christian Leutscher","doi":"10.5152/eurjrheum.2022.20105","DOIUrl":null,"url":null,"abstract":"We have read with interest the recent Letter to the Editor: “Remembering visceral leishmaniasis as a potential trigger of haemophagocytic lymphohistiocytosis in individuals treated with anti-TNF-alpha therapy” by Nardo-Marino et al., 1 and we would like to add some comments to the letter. This letter refers to a case report by Burka et al. 2 describing a Scandinavian male patient developing hemophagocytic lymphohistiocytosis 28days after the onset of infliximab treatment. The bone marrow examination revealed the presence of Leishmania amastiotes, which was a quite surprising finding, because the patient did not have any recent travel history to leishmaniasis-endemic areas at the onset of the symptoms and had never traveled to any endemic areas outside of Europe. The majority of visceral leishmaniasis (VL) cases worldwide occur in endemic areas of Brazil, Nepal, India, and in some East African countries. In Europe, the parasitic disease is seen in the Mediterranean region. 3 As highlighted by Nardo-Marino et al., 1 VL progression induced by biologic therapy has been reported on several occasions among patients from VL endemic areas. We have recently conducted a travel questionnaire survey among arthritis patients treated with biologics in our out-patient clinic. 4 A total of 273 patients completed the questionnaire. A history of traveling to dif-ferent countries in the Mediterranean region was reported by 13%, including Portugal, Spain, Italy,","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"9 2","pages":"114-115"},"PeriodicalIF":1.3000,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/79/81/ejr-9-2-114.PMC10176213.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of rheumatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5152/eurjrheum.2022.20105","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

We have read with interest the recent Letter to the Editor: “Remembering visceral leishmaniasis as a potential trigger of haemophagocytic lymphohistiocytosis in individuals treated with anti-TNF-alpha therapy” by Nardo-Marino et al., 1 and we would like to add some comments to the letter. This letter refers to a case report by Burka et al. 2 describing a Scandinavian male patient developing hemophagocytic lymphohistiocytosis 28days after the onset of infliximab treatment. The bone marrow examination revealed the presence of Leishmania amastiotes, which was a quite surprising finding, because the patient did not have any recent travel history to leishmaniasis-endemic areas at the onset of the symptoms and had never traveled to any endemic areas outside of Europe. The majority of visceral leishmaniasis (VL) cases worldwide occur in endemic areas of Brazil, Nepal, India, and in some East African countries. In Europe, the parasitic disease is seen in the Mediterranean region. 3 As highlighted by Nardo-Marino et al., 1 VL progression induced by biologic therapy has been reported on several occasions among patients from VL endemic areas. We have recently conducted a travel questionnaire survey among arthritis patients treated with biologics in our out-patient clinic. 4 A total of 273 patients completed the questionnaire. A history of traveling to dif-ferent countries in the Mediterranean region was reported by 13%, including Portugal, Spain, Italy,

Abstract Image

风湿病生物治疗患者利什曼原虫特异性抗体的筛选
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
56
审稿时长
7 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信